Healthcare
Prenetics Global Limited(PRE)
Live Price
Offline$20.50
+3.25% today
1Y Change
+166.05%
Window
Jun 23, 2025 β Jun 12, 2026
- Market Cap
- $240.00M
- Revenue Growth
- +201.7%
- EPS Growth
- -14.0%
- Dividend Yield
- 0.0%
Coverage: 245 bars Β· Jun 23, 2025 β Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Prenetics Global Limited (PRE) is a Healthcare stock with a market cap of $240.00M and listed on NASDAQ. The stock last traded around $20.50 and up 166.1% across the available one-year price window (Jun 23, 2025 β Jun 12, 2026). Baseline metrics include revenue growth of +201.7%, EPS growth of -14.0%, a dividend yield of 0.0%. What stands out right now is revenue +201.7%, EPS -14.0%, free cash flow +26.5% with operating margin -41.3% and ROIC -22.1%. Valuation is more restrained than many high-expectation growth names at price/sales 2.5. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines PRE price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+201.7% vs +7.6% peer median
Operating Margin
Below sector median
-41.3% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Jun 11, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +201.7% and EPS is at -14.0%, with operating margin around -41.3%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -8.2% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Jun 11, 2026 | β | +4.5% | β | β |
2026 Feb 18, 2026 | +44.9% | -3.8% | -15.6% | +2.0% |
2025 Nov 10, 2025 | +25.4% | +8.7% | -0.8% | +18.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PRE
β
Normalized return
SPY
β
S&P 500
Excess Return
β
Relative to SPY
PRE Max Drawdown
-34.36%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PRE and SPY.
Company Overview
Prenetics Global Limited
NASDAQ Global Market
Prenetics Global Limited, an investment holding company, operates as a diagnostics and genetic testing company. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring system that allows users to take COVID-19 tests at point-of-care or at home utilizing the nucleic acid amplification test. The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; Circle Medical, a diagnostic testing product; and Circle One and F1x/Fem. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.
- Leadership
- Sheng Wu Yeung
- IPO Date
- Jul 16, 2021
- Employees
- 285
- Street Address
- Unit 701-706, K11 Atelier Kingβs Road
- Mailing
- Quarry Bay
- Region
- Quarry Bay, HK
- Reporting Currency
- USD
- Investor Line
- 852 2210 9588
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- β
- EV/EBITDA
- β
- Price/Sales
- 2.5
- Price/Book
- 1.6
Growth
- Revenue
- +201.7%
- EPS
- -14.0%
- Free Cash Flow
- +26.5%
Profitability
- Gross Margin
- 53.0%
- Operating Margin
- -41.3%
- Net Margin
- -61.3%
- ROE
- -36.0%
- ROIC
- -22.1%
Balance Sheet
- Debt/Equity
- 0.01
- Current Ratio
- 3.01
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.